Vie Ventures

What Vie Ventures does

Vie Ventures is a Cambridge, MA-based life sciences venture capital firm founded in July 2025 that invests in Series B and C-stage private biotech companies developing novel therapeutics for autoimmune disease and other immune-mediated disorders. Its flagship vehicle, the Immunology & Autoimmune Fund LP, is offered privately to accredited investors and invests alongside other leading venture capital investors and strategic partners. The firm is co-founded by Steven St. Peter, MD (previously Managing Director of the T1D Fund with over $200M in AUM, and founder/CEO of NASDAQ-listed Aratana Therapeutics) and Luke Evnin, PhD (co-founder of MPM Capital with a track record of 50+ FDA-approved therapeutics and Chairman of the Scleroderma Research Foundation). Jeff Bluestone, PhD, the immunologist who created teplizumab, joined as Managing Director in February 2026.

The firm's core differentiator is its Strategic Collaborator Network — a coalition of 10+ disease-focused nonprofit organizations (including Crohn's & Colitis Foundation, Lupus Research Alliance, NMSS, Scleroderma Research Foundation, Sjögren's Foundation, American Diabetes Association, Arthritis Foundation, Beyond Celiac, Food Allergy Fund, FASI, Immune Boost Capital, and National Psoriasis Foundation) — which provides scientific insight, patient perspective, and development expertise to inform investment decisions. This network is formalized through the Therapeutics Advisory Council (TAC), inaugurated in September 2025, which operates as a cross-disease, cross-sector forum aligning mission-driven philanthropy with market-driven innovation.

Vie Ventures generates revenue through conventional venture capital economics on the I&A Fund LP: management fees on committed capital during the fund's investment period and carry on realized gains over the fund's life. The firm is sales-led, with go-to-market executed through industry events (JP Morgan Week, fireside chats, TAC meetings), earned media in tier-one biotech outlets, LinkedIn presence, and direct outreach to accredited LPs. Co-founders have aligned financial incentives with impact by pledging a share of proceeds and time to philanthropic efforts, including the formation of Vie Ventures Foundation.

Name

Vie Ventures

Legal name

Vie Ventures Inc.

Website

https://vieventures.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Vie Ventures is a Cambridge, MA life sciences venture capital firm that invests in Series B and C-stage biotechs developing therapeutics for autoimmune and immune-mediated diseases, leveraging a network of 10+ disease-focused philanthropy partners and scientific leaders like teplizumab inventor Jeff Bluestone.

Ownership category

akta.pro rank

Product category

Life Sciences Venture Capital

NAICS

Other Financial Vehicles (52599), Miscellaneous Intermediation (52391)

SIC

Investment Advice (6282)

akta.pro industry

PRIMARYFSANAAAD

Sector-Focused Venture Capital (Vertical Specialists)

Financial & Insurance/Private Equity & Venture Capital/Venture Capital Firms

Keywords

• Venture capital investing
• Life sciences fund
• Biotech equity investing
• Autoimmune therapeutics
• Disease-focused philanthropy

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Venture Capital Returns: Generates returns through equity investments in private biotech companies at Series B and Series C stages, alongside other leading venture capital investors and strategic partners.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Vie Ventures is a life sciences venture capital firm that invests alongside other leading venture capital investors and strategic partners in Series B and C-stage private biotech companies developing novel therapeutics for autoimmune disease and other disorders of the immune system. Its primary investment vehicle is the Immunology & Autoimmune Fund LP, a private offering to accredited investors. The firm differentiates itself through a network of strategic collaborators — disease-focused nonprofit foundations — that contribute scientific, clinical, and patient expertise into the investment and portfolio development process.

Product overview

Vie Ventures operates as a life sciences venture capital firm that bridges traditional biotech venture investing with patient-centric, disease-focused philanthropy. The core offering is the Immunology & Autoimmune Fund LP (I&A Fund), which invests in Series B and C-stage private biotech companies developing novel therapeutics for autoimmune diseases. This is supported by the Strategic Collaborator Network—a coalition of disease-focused nonprofit organizations contributing scientific expertise and patient networks—and the Therapeutics Advisory Council (TAC), which provides a structured forum for collaboration among foundations, scientists, and investors.

Differentiator

Problem solved

Functional benefit

Brands

• Immunology & Autoimmune Fund LP: The I&A Fund is a private offering to accredited investors focused on immunology and autoimmune diseases.

Products and services

• Immunology & Autoimmune Fund LP The firm's flagship private investment fund (a private offering to accredited investors) that invests alongside other venture capital investors and strategic partners in Series B and C-stage private biotech companies developing novel therapeutics for autoimmune disease and immune-mediated diseases.
• Strategic Collaborator Network A coalition of disease-focused nonprofit organizations (Crohn's & Colitis Foundation, Lupus Research Alliance, National Multiple Sclerosis Society, Scleroderma Research Foundation, Sjögren's Foundation, American Diabetes Association, Arthritis Foundation, Beyond Celiac, Food Allergy Fund, Immune Boost Capital, National Psoriasis Foundation, and Food Allergy Science Initiative) that contribute scientific insight, patient perspective, and development expertise to inform Vie Ventures' investment decisions and accelerate the path from discovery to patients.
• Therapeutics Advisory Council (TAC) A cross-disease, cross-sector forum designed to align mission-driven philanthropy with market-driven innovation to accelerate discovery and development of therapies for autoimmune and immune-mediated diseases by bringing together foundations, scientists, and investors.

Quantifiable outcome

• Over $200 million in assets managed through T1D Fund
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Eleven partnerships are on record, tiered core.

• Food Allergy Science Initiative (FASI)coreStrategic or Co-development Partner · 23 June 2026FASI has joined Vie Ventures as a Strategic Collaborator, bringing its network of over 100 scientists across 20+ laboratories to contribute scientific and clinical expertise toward Vie Ventures' investment and portfolio development activities in food allergy and immune-mediated diseases.
• American Diabetes AssociationcoreStrategic or Co-development Partner · 17 September 2025New strategic collaborator joining the Therapeutics Advisory Council, expanding the coalition of disease-focused philanthropies.
• Arthritis FoundationcoreStrategic or Co-development Partner · 17 September 2025New strategic collaborator providing arthritis-specific expertise and patient resources to the expanded collaborator network.
• Beyond CeliaccoreStrategic or Co-development Partner · 17 September 2025New strategic collaborator bringing celiac disease patient expertise and research infrastructure to Vie Ventures.
• Food Allergy FundcoreStrategic or Co-development Partner · 17 September 2025New strategic collaborator focused on food allergy research, expanding Vie Ventures' immune-mediated disease coverage.
• National Psoriasis FoundationcoreStrategic or Co-development Partner · 17 September 2025New strategic collaborator bringing psoriasis-specific disease expertise and patient networks to the coalition.
• Crohn's & Colitis FoundationcoreStrategic or Co-development Partner · 9 July 2025Initial strategic collaborator providing disease expertise, patient networks, and research infrastructure for IBD to inform investment decisions and accelerate therapeutic development.
• Lupus Research AlliancecoreStrategic or Co-development Partner · 9 July 2025Initial strategic collaborator bringing lupus-specific disease expertise and patient community insights to Vie Ventures' investment process.
• National Multiple Sclerosis SocietycoreStrategic or Co-development Partner · 9 July 2025Initial strategic collaborator focused on accelerating MS research through innovation, community, and measurable outcomes in partnership with Vie Ventures.
• Scleroderma Research FoundationcoreStrategic or Co-development Partner · 9 July 2025Initial strategic collaborator and co-founded by Luke Evnin, serving as Chairman. Largest funder of scleroderma discovery research and clinical development.
• Sjögren's FoundationcoreStrategic or Co-development Partner · 9 July 2025Initial strategic collaborator bringing Sjögren's disease expertise and patient networks to Vie Ventures' collaborative investment approach.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• RA Capital Management: Healthcare-focused investment firm with deep expertise in clinical and scientific due diligence. Directly comparable in its thesis-driven approach to biotech venture and crossover investing in private and public immunology companies.
• Orbimed: One of the largest healthcare-dedicated investment firms globally, with significant activity in biotech venture and growth equity. Directly comparable in therapeutic-area focus and late-stage private biotech investing mandate.
• Atlas Venture: Early-stage life sciences venture firm focused on building biotech companies from inception. Comparable in dedicated life sciences focus and company-creation approach, though Atlas leans earlier-stage than Vie Ventures' Series B/C mandate.
• 5AM Ventures: Early-stage life sciences venture firm with a track record of building biotech companies around academic and clinical science. Comparable in its focus on founder-driven biotechs and therapeutic-area specialization.
• ARCH Venture Partners: Large, established life sciences and technology venture firm with deep scientific networks and significant autoimmune/immunology exposure. Comparable in the breadth of its scientific advisor network and ability to lead large biotech financings.
• Versant Ventures: Healthcare-focused venture firm investing across biotech, medtech, and healthcare services. Comparable in its life sciences focus, multi-stage mandate, and company-building orientation in therapeutics.
• Baker Brothers Life Sciences: Long-tenured life sciences-focused investment firm with deep public and private biotech exposure. Comparable in its concentrated, long-duration, science-driven approach to biotech investing across stages.
• Foresite Capital: Healthcare and life sciences investment firm that partners with entrepreneurs and institutions to build companies. Comparable in its focus on therapeutic platforms and the integration of scientific advisors into the investment process.
• MPM Capital: Life sciences venture capital firm co-founded by Luke Evnin, where both Vie Ventures founders previously worked together for a decade. Direct peer in therapeutic-area-focused biotech investing and the natural benchmark for the new I&A Fund.

Broad incumbents

• New Enterprise Associates (NEA): Large, multi-stage venture firm with a significant healthcare and life sciences practice. Less narrowly focused on autoimmune disease than Vie Ventures, but comparable in deploying large life sciences venture funds alongside strategic and institutional LPs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/vie-ventures

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vie Ventures